241 related articles for article (PubMed ID: 33264017)
41. Evaluation of Poly(ADP-ribose) Polymerase Inhibitor, Pamiparib (BGB-290) in Treating Acute Myeloid Leukemia and the Characterization of Its Nanocarrier.
Xu X; Wang J; Tong T; Lin SF; Liu C; Zhou D
J Biomed Nanotechnol; 2021 Nov; 17(11):2165-2175. PubMed ID: 34906277
[TBL] [Abstract][Full Text] [Related]
42. Stepwise development of structure-activity relationship of diverse PARP-1 inhibitors through comparative and validated in silico modeling techniques and molecular dynamics simulation.
Halder AK; Saha A; Saha KD; Jha T
J Biomol Struct Dyn; 2015; 33(8):1756-79. PubMed ID: 25350685
[TBL] [Abstract][Full Text] [Related]
43. A comprehensive look of poly(ADP-ribose) polymerase inhibition strategies and future directions for cancer therapy.
Kumar C; Rani N; Velan Lakshmi PT; Arunachalam A
Future Med Chem; 2017 Jan; 9(1):37-60. PubMed ID: 27995810
[TBL] [Abstract][Full Text] [Related]
44. Evaluation of
Liao M; Jaw-Tsai S; Beltman J; Simmons AD; Harding TC; Xiao JJ
Xenobiotica; 2020 Sep; 50(9):1032-1042. PubMed ID: 32129697
[TBL] [Abstract][Full Text] [Related]
45. Synthesis and evaluation of tricyclic derivatives containing a non-aromatic amide as inhibitors of poly(ADP-ribose)polymerase-1 (PARP-1).
Park CH; Chun K; Joe BY; Park JS; Kim YC; Choi JS; Ryu DK; Koh SH; Cho GW; Kim SH; Kim MH
Bioorg Med Chem Lett; 2010 Apr; 20(7):2250-3. PubMed ID: 20189385
[TBL] [Abstract][Full Text] [Related]
46. Discovery of isoquinolinone and naphthyridinone-based inhibitors of poly(ADP-ribose) polymerase-1 (PARP1) as anticancer agents: Structure activity relationship and preclinical characterization.
Karche NP; Bhonde M; Sinha N; Jana G; Kukreja G; Kurhade SP; Jagdale AR; Tilekar AR; Hajare AK; Jadhav GR; Gupta NR; Limaye R; Khedkar N; Thube BR; Shaikh JS; Rao Irlapati N; Phukan S; Gole G; Bommakanti A; Khanwalkar H; Pawar Y; Kale R; Kumar R; Gupta R; Praveen Kumar VR; Wahid S; Francis A; Bhat T; Kamble N; Patil V; Nigade PB; Modi D; Pawar S; Naidu S; Volam H; Pagdala V; Mallurwar S; Goyal H; Bora P; Ahirrao P; Singh M; Kamalakannan P; Naik KR; Kumar P; Powar RG; Shankar RB; Bernstein PR; Gundu J; Nemmani K; Narasimham L; George KS; Sharma S; Bakhle D; Kamboj RK; Palle VP
Bioorg Med Chem; 2020 Dec; 28(24):115819. PubMed ID: 33120078
[TBL] [Abstract][Full Text] [Related]
47. Pamiparib: First Approval.
Markham A
Drugs; 2021 Jul; 81(11):1343-1348. PubMed ID: 34287805
[TBL] [Abstract][Full Text] [Related]
48. Poly(ADP-ribose) polymerase-1 (PARP-1) inhibitors in cancer chemotherapy.
Cepeda V; Fuertes MA; Castilla J; Alonso C; Quevedo C; Soto M; Pérez JM
Recent Pat Anticancer Drug Discov; 2006 Jan; 1(1):39-53. PubMed ID: 18221025
[TBL] [Abstract][Full Text] [Related]
49. Structure-Based Pharmacophore Modeling, Virtual Screening, Molecular Docking and Biological Evaluation for Identification of Potential Poly (ADP-Ribose) Polymerase-1 (PARP-1) Inhibitors.
Zhou Y; Tang S; Chen T; Niu MM
Molecules; 2019 Nov; 24(23):. PubMed ID: 31766720
[TBL] [Abstract][Full Text] [Related]
50. Capturing a Pentacyclic Fragment-Based Library Derived from Perophoramidine: Their Design, Synthesis and Evaluation as Anticancer Compounds by DNA Double-Strand Breaks (DSB) and PARP-1 Inhibition.
Guha S; Yussif El-Deeb I; Yadav S; Das R; Dutta Dubey K; Baruah M; Gremaud L; Sen S
Chemistry; 2022 Nov; 28(63):e202202405. PubMed ID: 35952312
[TBL] [Abstract][Full Text] [Related]
51. An Update on Poly(ADP-ribose)polymerase-1 (PARP-1) Inhibitors: Opportunities and Challenges in Cancer Therapy.
Wang YQ; Wang PY; Wang YT; Yang GF; Zhang A; Miao ZH
J Med Chem; 2016 Nov; 59(21):9575-9598. PubMed ID: 27416328
[TBL] [Abstract][Full Text] [Related]
52. In silico investigation of PARP-1 catalytic domains in holo and apo states for the design of high-affinity PARP-1 inhibitors.
Salmas RE; Unlu A; Yurtsever M; Noskov SY; Durdagi S
J Enzyme Inhib Med Chem; 2016; 31(1):112-20. PubMed ID: 26083304
[TBL] [Abstract][Full Text] [Related]
53. [From poly(ADP-ribose) discovery to PARP inhibitors in cancer therapy].
Schreiber V; Illuzzi G; Héberlé E; Dantzer F
Bull Cancer; 2015 Oct; 102(10):863-73. PubMed ID: 26384693
[TBL] [Abstract][Full Text] [Related]
54. Identification of novel PARP-1 inhibitors by structure-based virtual screening.
Hannigan K; Kulkarni SS; Bdzhola VG; Golub AG; Yarmoluk SM; Talele TT
Bioorg Med Chem Lett; 2013 Nov; 23(21):5790-4. PubMed ID: 24074844
[TBL] [Abstract][Full Text] [Related]
55. Structural basis for inhibitor specificity in human poly(ADP-ribose) polymerase-3.
Lehtiö L; Jemth AS; Collins R; Loseva O; Johansson A; Markova N; Hammarström M; Flores A; Holmberg-Schiavone L; Weigelt J; Helleday T; Schüler H; Karlberg T
J Med Chem; 2009 May; 52(9):3108-11. PubMed ID: 19354255
[TBL] [Abstract][Full Text] [Related]
56. Identification of potent nontoxic poly(ADP-Ribose) polymerase-1 inhibitors: chemopotentiation and pharmacological studies.
Calabrese CR; Batey MA; Thomas HD; Durkacz BW; Wang LZ; Kyle S; Skalitzky D; Li J; Zhang C; Boritzki T; Maegley K; Calvert AH; Hostomsky Z; Newell DR; Curtin NJ
Clin Cancer Res; 2003 Jul; 9(7):2711-8. PubMed ID: 12855651
[TBL] [Abstract][Full Text] [Related]
57. Design, synthesis and biological activity of novel molecules designed to target PARP and DNA.
Goodfellow E; Senhaji Mouhri Z; Williams C; Jean-Claude BJ
Bioorg Med Chem Lett; 2017 Feb; 27(3):688-694. PubMed ID: 28003142
[TBL] [Abstract][Full Text] [Related]
58. PARP inhibitors for cancer therapy.
Curtin NJ
Expert Rev Mol Med; 2005 Mar; 7(4):1-20. PubMed ID: 15836799
[TBL] [Abstract][Full Text] [Related]
59. Synthesis and structure-activity relationships of novel poly(ADP-ribose) polymerase-1 inhibitors.
Tao M; Park CH; Bihovsky R; Wells GJ; Husten J; Ator MA; Hudkins RL
Bioorg Med Chem Lett; 2006 Feb; 16(4):938-42. PubMed ID: 16290935
[TBL] [Abstract][Full Text] [Related]
60. Serendipitous discovery of a prodrug of a PARP-1 inhibitor.
Dunn D; Husten J; Aimone LD; Ator MA; Chatterjee S
Chem Biol Drug Des; 2013 Sep; 82(3):348-50. PubMed ID: 23679830
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]